| Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia DL Rolnik, D Wright, LC Poon, N O’Gorman, A Syngelaki, ... New England Journal of Medicine 377 (7), 613-622, 2017 | 2034 | 2017 |
| Evaluation of intranasal delivery route of drug administration for brain targeting F Erdő, LA Bors, D Farkas, Á Bajza, S Gizurarson Brain research bulletin 143, 155-170, 2018 | 584 | 2018 |
| Anatomical and histological factors affecting intranasal drug and vaccine delivery S Gizurarson Current drug delivery 9 (6), 566-582, 2012 | 254 | 2012 |
| Animal models for intranasal drug delivery studies. A review article. S Gizurarson Acta pharmaceutica nordica 2 (2), 105-122, 1990 | 171 | 1990 |
| The relevance of nasal physiology to the design of drug absorption studies S Gizurarson Advanced drug delivery reviews 11 (3), 329-347, 1993 | 135 | 1993 |
| Method of administering a biologically active substance E Bechgaard, S Gizurarson, RK Hjortkjaer US Patent 5,428,006, 1995 | 127 | 1995 |
| The effect of cilia and the mucociliary clearance on successful drug delivery S Gizurarson Biological and Pharmaceutical Bulletin 38 (4), 497-506, 2015 | 116 | 2015 |
| Pharmaceutical preparation E Bechgaard, S Gizurarson, RK Hjortkjaer US Patent 5,397,771, 1995 | 115 | 1995 |
| Placental protein 13 (PP13)–a placental immunoregulatory galectin protecting pregnancy NG Than, A Balogh, R Romero, É Kárpáti, O Erez, A Szilágyi, I Kovalszky, ... Frontiers in immunology 5, 348, 2014 | 114 | 2014 |
| Method of administering a biologically active substance E Bechgaard, S Gizurarson US Patent 5,693,608, 1997 | 107 | 1997 |
| Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia B Huppertz, H Meiri, S Gizurarson, G Osol, M Sammar Human reproduction update 19 (4), 391-405, 2013 | 94 | 2013 |
| Intranasal administration of insulin to humans S Gizurarson, E Bechgaard Diabetes research and clinical practice 12 (2), 71-84, 1991 | 80 | 1991 |
| The influence of insulin and some excipients used in nasal insulin preparations on mucociliary clearance S Gizurarson, C Marriott, GP Martin, E Bechgaard International journal of pharmaceutics 65 (3), 243-247, 1990 | 69 | 1990 |
| Modulation of immune responses using adjuvants to facilitate therapeutic vaccination V Schijns, A Fernández‐Tejada, Ž Barjaktarović, I Bouzalas, J Brimnes, ... Immunological reviews 296 (1), 169-190, 2020 | 68 | 2020 |
| Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections H Jakobsen, E Saeland, S Gizurarson, D Schulz, I Jónsdóttir Infection and immunity 67 (8), 4128-4133, 1999 | 67 | 1999 |
| Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit S Gizurarson, S Tamura, C Aizawa, T Kurata Vaccine 10 (2), 101-106, 1992 | 66 | 1992 |
| Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits E Bechgaard, S Gizurarson, RK Hjortkjær Journal of pharmacy and pharmacology 49 (8), 747-750, 1997 | 61 | 1997 |
| Intranasal booster vaccination against diphtheria and tetanus in man H Aggerbeck, S Gizurarson, J Wantzin, I Heron Vaccine 15 (3), 307-316, 1997 | 61 | 1997 |
| Absorption promoting agent S Gizurarson, S Olafsdottir, JL Kristinsson, K Hrafnkelsdottir, DR Olafsson, ... US Patent 6,855,332, 2005 | 60 | 2005 |
| Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane S Gizurarson, I Heron US Patent 5,942,237, 1999 | 60 | 1999 |
